Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling
- 149 Downloads
The aims of this study were to develop a population pharmacokinetic (PPK) model of lamotrigine (LTG) in Chinese epileptic children by using nonlinear mixed effects modeling (NONMEM) and to investigate the effects of valproic acid (VPA) and genetic polymorphisms of the major metabolizing enzymes (UGT1A4, UGT2B7) on the pharmacokinetics of LTG.
A total of 182 epileptic children who were treated with LTG as monotherapy or as part of combination therapy were included in this study as the model group, and 61 patients were included as the validation group. The steady-state serum trough concentrations of LTG and VPA were determined using a high-performance liquid chromatography method and fluorescence polarization immunoassay, respectively. Patients were genotyped for three single nucleotide polymorphisms (UGT1A4 142T>G, UGT2B7 −161C>T, and UGT2B7 802C>T). PPK analysis was performed with NONMEM using first-order absorption and elimination. Bootstrap, normalized prediction distribution errors and external evaluations were performed to determine the stability and predictive performance of the model.
For the final model, the oral clearance (CL/F) of LTG was estimated to be 0.705 L/h with inter-individual variability (IIV) of 21.3%. The estimates generated by NONMEM indicated that the LTG CL/F was significantly influenced by patient body weight (increased with an exponent of 0.574) and VPA concentration (decreased with linearity of 0.273 with co-administration). However, no significant effects of UGT1A4 or UGT2B7 polymorphisms on LTG CL/F were noted in this population of Chinese children.
This study confirms the interaction of LTG with VPA, which likely depends on VPA concentration. The LTG PPK model developed in this study could be useful for individualizing LTG dosage regimens in pediatric patients receiving combination therapy, especially therapy that includes VPA.
KeywordsPopulation pharmacokinetics Lamotrigine Valproic acid UGT polymorphisms Chinese children
The authors would like to thank Professor Zheng Jiao from Huashan Hospital, Fudan University, China, for his invaluable advice and support. This project was supported by grants from the National Natural Science Foundation of China (No. 81673510 and 81703628).
Compliance with ethical standards
All patients’ guardians were informed about the purpose of the study, and the Shengjing Hospital ethics committee approved the study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 7.Blanca SM, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, Nicolas JM, Adin J, Shushtarian M, Armijo JA (2010) UGT2B7–161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 32(2):177–184Google Scholar
- 9.Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y (2015) Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol 71(11):1341–1347. https://doi.org/10.1007/s00228-015-1925-9 CrossRefPubMedGoogle Scholar
- 15.Milosheska D, Lorber B, Vovk T, Kastelic M, Dolžan V, Grabnar I (2016) Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol 82(2):399–411. https://doi.org/10.1111/bcp.12984 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Chung JY, Cho JY, KS Y, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83(4):595–600. https://doi.org/10.1038/sj.clpt.6100324 CrossRefPubMedGoogle Scholar
- 23.Brzaković B, Vučićević K, Kovačević SV, Miljković B, Prostran M, Martinović Ž, Pokrajac M (2014) Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients—nonlinear mixed effects modelling approach. Eur J Clin Pharmacol 70(2):179–185. https://doi.org/10.1007/s00228-013-1606-5 CrossRefPubMedGoogle Scholar
- 28.Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, Owada E, Miyamoto A (2006) Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 39(3):303–308. https://doi.org/10.1016/j.clinbiochem.2006.01.002 CrossRefPubMedGoogle Scholar
- 31.Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z (2015) A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet 54(3):305–317. https://doi.org/10.1007/s40262-014-0212-8 CrossRefPubMedGoogle Scholar
- 33.Tunblad K, Lindbom L, McFadyen L, Jonsson EN, Marshall S, Karlsson MO (2008) The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn 35(5):503–526. https://doi.org/10.1007/s10928-008-9099-z CrossRefPubMedGoogle Scholar
- 36.GlaxoSmithKline UK (2017) Summary of product characteristics for Lamictal. Available at http://www.medicines.org.uk/emc/medicine/4228/SPC/Lamictal/#FORM. Accessed 20 September 2017
- 39.Ahn JE, Birnbaum AK, Brundage RC (2005) Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn 32(5–6):703–718. https://doi.org/10.1007/s10928-005-0083-6 CrossRefPubMedGoogle Scholar
- 43.Inoue K, Yamamoto Y, Suzuki E, Takahashi T, Umemura A, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K (2016) Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. Eur J Clin Pharmacol 72(5):555–562. https://doi.org/10.1007/s00228-016-2008-2 CrossRefPubMedGoogle Scholar